Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplasms, Plasma Cell

ClinicalTrials.gov lists 4,341 trials for Neoplasms, Plasma Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 186.

MeSH D054219 Neoplasms Neoplasm C04 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,011 Phase 1/2 Phase 1/2 523 Phase 2 Phase 2 1,339 Phase 2/3 Phase 2/3 37 Phase 3 Phase 3 379 Phase 4 Phase 4 62 Not applicable Not applicable 384 Observational Observational 571 Phase 1 Phase 1 1,011 Phase 1/2 Phase 1/2 523 Phase 2 Phase 2 1,339 Phase 2/3 Phase 2/3 37 Phase 3 Phase 3 379 Phase 4 Phase 4 62 Not applicable Not applicable 384 Observational Observational 571

Trials per phase (log scale)

2 more sections with rows

703 of the 4,341 trials are tagged with Neoplasms, Plasma Cell itself; the rest are tagged with a narrower condition beneath it.

Get the Neoplasms, Plasma Cell report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplasms, Plasma Cell trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 12 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 227

1990: 1 trials (Phase 2 1) 1991: 1 trials (Phase 2 1) 1992: 4 trials (Phase 2 2, Phase 1/2 1, Phase 1 1) 1993: 6 trials (Observational 2, Phase 3 1, Phase 2 3) 1994: 6 trials (Phase 3 3, Phase 2 3) 1995: 10 trials (Phase 3 4, Phase 2 4, Phase 1/2 1, Phase 1 1) 1996: 15 trials (Observational 1, Phase 3 4, Phase 2 8, Phase 1 2) 1997: 29 trials (Observational 1, Not applicable 3, Phase 3 5, Phase 2 13, Phase 1/2 2, Phase 1 5) 1998: 54 trials (Not applicable 2, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 32, Phase 1/2 2, Phase 1 10) 1999: 53 trials (Not applicable 4, Phase 3 8, Phase 2 25, Phase 1/2 5, Phase 1 11) 2000: 60 trials (Observational 2, Not applicable 5, Phase 3 15, Phase 2/3 1, Phase 2 23, Phase 1/2 9, Phase 1 5) 2001: 57 trials (Observational 4, Not applicable 7, Phase 4 1, Phase 3 5, Phase 2/3 2, Phase 2 21, Phase 1/2 7, Phase 1 10) 2002: 73 trials (Observational 5, Not applicable 5, Phase 3 10, Phase 2/3 1, Phase 2 32, Phase 1/2 9, Phase 1 11) 2003: 78 trials (Observational 3, Not applicable 8, Phase 4 1, Phase 3 16, Phase 2/3 1, Phase 2 20, Phase 1/2 11, Phase 1 18) 2004: 102 trials (Observational 5, Not applicable 7, Phase 4 3, Phase 3 8, Phase 2/3 2, Phase 2 46, Phase 1/2 13, Phase 1 18) 2005: 121 trials (Observational 7, Not applicable 8, Phase 4 1, Phase 3 12, Phase 2 51, Phase 1/2 16, Phase 1 26) 2006: 130 trials (Observational 14, Not applicable 6, Phase 4 2, Phase 3 20, Phase 2 48, Phase 1/2 16, Phase 1 24) 2007: 135 trials (Other 1, Observational 8, Not applicable 7, Phase 4 2, Phase 3 12, Phase 2/3 1, Phase 2 52, Phase 1/2 16, Phase 1 36) 2008: 165 trials (Observational 21, Not applicable 6, Phase 3 16, Phase 2/3 1, Phase 2 59, Phase 1/2 16, Phase 1 46) 2009: 135 trials (Other 2, Observational 18, Not applicable 7, Phase 3 16, Phase 2/3 4, Phase 2 41, Phase 1/2 20, Phase 1 27) 2010: 162 trials (Observational 20, Not applicable 10, Phase 4 3, Phase 3 13, Phase 2 59, Phase 1/2 27, Phase 1 30) 2011: 132 trials (Observational 15, Not applicable 10, Phase 4 1, Phase 3 13, Phase 2 41, Phase 1/2 23, Phase 1 29) 2012: 152 trials (Observational 14, Not applicable 8, Phase 4 1, Phase 3 7, Phase 2 62, Phase 1/2 23, Phase 1 37) 2013: 132 trials (Observational 17, Not applicable 9, Phase 4 1, Phase 3 12, Phase 2/3 1, Phase 2 39, Phase 1/2 23, Phase 1 30) 2014: 158 trials (Observational 15, Not applicable 11, Phase 4 2, Phase 3 11, Phase 2/3 1, Phase 2 45, Phase 1/2 20, Phase 1 53) 2015: 153 trials (Observational 22, Not applicable 8, Phase 4 2, Phase 3 14, Phase 2/3 1, Phase 2 55, Phase 1/2 15, Phase 1 36) 2016: 154 trials (Observational 23, Not applicable 11, Phase 4 4, Phase 3 9, Phase 2 57, Phase 1/2 19, Phase 1 31) 2017: 179 trials (Observational 27, Not applicable 9, Phase 4 1, Phase 3 16, Phase 2/3 1, Phase 2 54, Phase 1/2 26, Phase 1 45) 2018: 170 trials (Observational 27, Not applicable 12, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 62, Phase 1/2 17, Phase 1 41) 2019: 190 trials (Observational 27, Not applicable 11, Phase 4 7, Phase 3 13, Phase 2/3 1, Phase 2 50, Phase 1/2 29, Phase 1 52) 2020: 169 trials (Observational 35, Not applicable 26, Phase 4 2, Phase 3 13, Phase 2/3 2, Phase 2 34, Phase 1/2 11, Phase 1 46) 2021: 227 trials (Observational 36, Not applicable 22, Phase 4 2, Phase 3 11, Phase 2 65, Phase 1/2 25, Phase 1 66) 2022: 222 trials (Observational 48, Not applicable 28, Phase 4 6, Phase 3 13, Phase 2/3 1, Phase 2 46, Phase 1/2 23, Phase 1 57) 2023: 218 trials (Observational 45, Not applicable 33, Phase 4 2, Phase 3 13, Phase 2/3 2, Phase 2 46, Phase 1/2 32, Phase 1 45) 2024: 198 trials (Observational 42, Not applicable 28, Phase 4 3, Phase 3 16, Phase 2 35, Phase 1/2 21, Phase 1 53) 2025: 207 trials (Observational 32, Not applicable 41, Phase 4 5, Phase 3 11, Phase 2/3 6, Phase 2 51, Phase 1/2 19, Phase 1 42)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 216
2025 207
2024 198
2023 218
2022 222
2021 227
2020 169
2019 190
2018 170
2017 179

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 240 trials starting in 2026 and about 220 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 548 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 2,676 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplasms, Plasma Cell trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,011
Phase 1/2 523
Phase 2 1,339
Phase 2/3 37
Phase 3 379
Phase 4 62
Not applicable 384
Observational 571
Expanded access 34
Unknown 1

How many Neoplasms, Plasma Cell trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 168
Recruiting 619
Enrolling by invitation 13
Active, not recruiting 338
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplasms, Plasma Cell trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 186
Celgene 93
Janssen Research & Development, LLC 66
GlaxoSmithKline 47
Amgen 43

Which drugs are being tested for Neoplasms, Plasma Cell? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 354
Melphalan 249
POMALIDOMIDE 192
RITUXIMAB 111
THALIDOMIDE 107

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 770
Bortezomib SC 436
X: Lenalidomide 413
SQ Fludarabine 229
Daratumumab SC 211

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplasms, Plasma Cell trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 4,713 323
Pyrexia 1,606 220
Thrombocytopenia 1,345 182
Sepsis 1,300 310
Febrile neutropenia 1,288 242

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplasms, Plasma Cell? (15)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study. Haematologica 2024 Yes
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study. Haematologica 2024 Yes
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood cancer journal 2024 Yes
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood cancer journal 2023 Yes
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leukemia & lymphoma 2023 Yes

Showing 5 of 15 publications.

Start your 14-day trial Email me all 15 publications as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Plasma cell tumor 98282 Exact Orphadata Science knowledge files, Product 1
Plasma cell tumor 98282 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence.

Browse all condition evidence pages